Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

UDG Healthcare’s Chris Corbin to retire

CEO of Ashfield Commercial & Medical Services to step down in 2019

- PMLiVE

Edelman strengthens healthcare team

Appoints Vicky Bramham, Louise Daltan and Emma Coughlan

- PMLiVE

Global Pricing Innovations and Partners4Access partner on market access

Will collaborate on orphan drug pricing and access solutions

- PMLiVE

Man Boobs campaign wins at D&AD Impact Awards

Takes home White Pencil in inaugural awards for creative contribution to society

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

- PMLiVE

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Licenses two gene silencing programmes with up to $670m in the offing for the specialist

- PMLiVE

How merging firms can manage culture change

Addressing the potential problems and finding the solutions

- PMLiVE

Getting below the surface: regional and local market access

Gaining access to a national market is a key hurdle in a drug’s life cycle, as is getting through the maze of the different health technology assessments (HTAs) and pricing...

- PMLiVE

Nouscom appoints COO and board members

Dr Marina Udier Blagovic takes on newly-created role while three join board

- PMLiVE

Novo Nordisk to cut 1,000 jobs as diabetes competition builds

Cites intensifying US market in particular for move to reduce costs

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links